ClariTrial | Search Clinical Trials

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,367 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 425

Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Phase 1Phase 2Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBC

JAB-2485 (Aurora A inhibitor)JAB-2485 (Aurora A inhibitor)

Jacobio Pharmaceuticals Co., Ltd.102 participants8 sites · United States, ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Phase 1Phase 2Lung CancerLung Cancer MetastaticLung Cancer, Non-small Cell

Tumor Infiltrating Lymphocytes (TIL)CyclophosphamideFludarabine+2 more

Essen Biotech85 participants1 site · ChinaCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

Phase 3Carcinoma, Ovarian EpithelialLow Grade Serous Adenocarcinoma of Ovary

Letrozole tabletscarboplatin AUC 5 and paclitaxel 175 mg/m2

Ente Ospedaliero Ospedali Galliera132 participants19 sites · ItalyCompletes Sep 2029

Compare CT.gov Full analysis →

Recruiting

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Phase 2Head and Neck Cancer

radical radiotherapy (60Gy)radical radiotherapy (66Gy)radical radiotherapy (70Gy)+1 more

Cancer Institute and Hospital, Chinese Academy of Medical Sciences133 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Phase 3Childhood Extracranial Germ Cell TumorExtragonadal Embryonal CarcinomaGerm Cell Tumor

Best PracticeBiopsy ProcedureBiospecimen Collection+8 more

Children's Oncology Group1,780 participants629 sites · United States, Australia, CanadaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Phase 2Non-Small Cell Lung Cancer

BL-B01D1Almonertinib

Sichuan University40 participants1 site · ChinaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Phase 2HER2-positive Early Breast Cancer

Nab paclitaxelCarboplatinTrastuzumab+3 more

Second Affiliated Hospital, Zhejiang University, School of Medicine200 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Bovine Reinforcement in Stomach, Colorectal and Lung Operation

Phase 3Rectal Cancer Stage IIILung Cancer Stage III

Bioabsorbable Staple Line Reinforcemen

Shanghai Cingularbio Co. Ltd172 participants1 site · ChinaCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

Phase 3Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8

Biospecimen CollectionEducational InterventionExtended Release Metformin Hydrochloride+1 more

City of Hope Medical Center80 participants3 sites · United StatesCompletes Jun 2031

Compare CT.gov Full analysis →

Recruiting

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Phase 3Lymphoma, T-Cell, Peripheral

CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)TucidinostatPlacebo

Chipscreen Biosciences, Ltd.224 participants1 site · ChinaCompletes Dec 2032

Compare CT.gov Full analysis →

Recruiting

Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

Phase 2Pancreatic Cancer

SHR-A2102 or/and HRS-4642SHR-A1904 or/and HRS-4642SHR-A1811 or/and HRS-4642+1 more

Fudan University160 participants1 site · ChinaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Phase 1Phase 2Anaplastic OligodendrogliomaAstrocytoma, IDH-Mutant, Grade 3Astrocytoma, IDH-Mutant, Grade 4

Biospecimen CollectionEflornithineLumbar Puncture+3 more

Mayo Clinic33 participants1 site · United StatesCompletes Oct 2030

Compare CT.gov Full analysis →

Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

Phase 2Phase 3Haematological MalignancyMalignancyMalignant Neoplasm

Entrectinib

Cancer Research UK30 participants27 sites · United KingdomCompletes Oct 2029

Compare CT.gov Full analysis →

Recruiting

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

Phase 2Locally Advanced Hepatocellular Carcinoma

SIRT-Y90 with Atezolizumab + BevacizumabSIRT-Y90 with Placebo (IV)

National Cancer Centre, Singapore100 participants14 sites · China, Singapore, South KoreaCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Phase 2HCC - Hepatocellular CarcinomaTremelimumabDurvalumab

Photon radiotherapyTremelimumabDurvalumab

Chang Gung Memorial Hospital45 participants1 site · TaiwanCompletes May 2030

Compare CT.gov Full analysis →

1–15 of 6,367

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,367 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 425

Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Phase 1Phase 2Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBC

JAB-2485 (Aurora A inhibitor)JAB-2485 (Aurora A inhibitor)

Jacobio Pharmaceuticals Co., Ltd.102 participants8 sites · United States, ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Phase 1Phase 2Lung CancerLung Cancer MetastaticLung Cancer, Non-small Cell

Tumor Infiltrating Lymphocytes (TIL)CyclophosphamideFludarabine+2 more

Essen Biotech85 participants1 site · ChinaCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

Phase 3Carcinoma, Ovarian EpithelialLow Grade Serous Adenocarcinoma of Ovary

Letrozole tabletscarboplatin AUC 5 and paclitaxel 175 mg/m2

Ente Ospedaliero Ospedali Galliera132 participants19 sites · ItalyCompletes Sep 2029

Compare CT.gov Full analysis →

Recruiting

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Phase 2Head and Neck Cancer

radical radiotherapy (60Gy)radical radiotherapy (66Gy)radical radiotherapy (70Gy)+1 more

Cancer Institute and Hospital, Chinese Academy of Medical Sciences133 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Phase 3Childhood Extracranial Germ Cell TumorExtragonadal Embryonal CarcinomaGerm Cell Tumor

Best PracticeBiopsy ProcedureBiospecimen Collection+8 more

Children's Oncology Group1,780 participants629 sites · United States, Australia, CanadaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Phase 2Non-Small Cell Lung Cancer

BL-B01D1Almonertinib

Sichuan University40 participants1 site · ChinaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Phase 2HER2-positive Early Breast Cancer

Nab paclitaxelCarboplatinTrastuzumab+3 more

Second Affiliated Hospital, Zhejiang University, School of Medicine200 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Bovine Reinforcement in Stomach, Colorectal and Lung Operation

Phase 3Rectal Cancer Stage IIILung Cancer Stage III

Bioabsorbable Staple Line Reinforcemen

Shanghai Cingularbio Co. Ltd172 participants1 site · ChinaCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

Phase 3Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8

Biospecimen CollectionEducational InterventionExtended Release Metformin Hydrochloride+1 more

City of Hope Medical Center80 participants3 sites · United StatesCompletes Jun 2031

Compare CT.gov Full analysis →

Recruiting

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Phase 3Lymphoma, T-Cell, Peripheral

CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)TucidinostatPlacebo

Chipscreen Biosciences, Ltd.224 participants1 site · ChinaCompletes Dec 2032

Compare CT.gov Full analysis →

Recruiting

Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

Phase 2Pancreatic Cancer

SHR-A2102 or/and HRS-4642SHR-A1904 or/and HRS-4642SHR-A1811 or/and HRS-4642+1 more

Fudan University160 participants1 site · ChinaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Phase 1Phase 2Anaplastic OligodendrogliomaAstrocytoma, IDH-Mutant, Grade 3Astrocytoma, IDH-Mutant, Grade 4

Biospecimen CollectionEflornithineLumbar Puncture+3 more

Mayo Clinic33 participants1 site · United StatesCompletes Oct 2030

Compare CT.gov Full analysis →

Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

Phase 2Phase 3Haematological MalignancyMalignancyMalignant Neoplasm

Entrectinib

Cancer Research UK30 participants27 sites · United KingdomCompletes Oct 2029

Compare CT.gov Full analysis →

Recruiting

Phase 2Locally Advanced Hepatocellular Carcinoma

SIRT-Y90 with Atezolizumab + BevacizumabSIRT-Y90 with Placebo (IV)

National Cancer Centre, Singapore100 participants14 sites · China, Singapore, South KoreaCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

Phase 2HCC - Hepatocellular CarcinomaTremelimumabDurvalumab

Photon radiotherapyTremelimumabDurvalumab

Chang Gung Memorial Hospital45 participants1 site · TaiwanCompletes May 2030

Compare CT.gov Full analysis →

1–15 of 6,367